Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIS793 and FOLFIRINOX in Pancreatic Cancer
NCT05417386Phase 1Terminated
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nisevokitug in pancreatic adenocarcinoma (PDAC). Started Aug 2022; status: terminated.
02
Drugs
nisevokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05417386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417386.